Engineered OVs can also introduce specific therapeutic genes including tumor-suppressor genes (i.e., p53, [845]), anti-angiogenic genes [846], and immunostimulatory genes [847], or induce PI3K inhibition [848,849] in GB cells to execute their expression. Here, PIK3CA is linked to neoplasm.